title: A mechanistic pharmacokinetic/pharmacodynamic model of factor D inhibition in cynomolgus monkeys by lampalizumab for the treatment of geographic atrophy.
abstract: Lampalizumab is an antigen-binding fragment of a humanized monoclonal antibody against complement factor D (CFD), a rate-limiting enzyme in the activation and amplification of the alternative complement pathway (ACP), which is in phase III clinical trials for the treatment of geographic atrophy. Understanding of the pharmacokinetics, pharmacodynamics, and biodistribution of lampalizumab following intravitreal administration in the ocular compartments and systemic circulation is limited but crucial for selecting doses that provide optimal efficacy and safety. Here, we sought to construct a semimechanistic and integrated ocular-systemic pharmacokinetic-pharmacodynamic model of lampalizumab in the cynomolgus monkey to provide a quantitative understanding of the ocular and systemic disposition of lampalizumab and CFD inhibition. The model takes into account target-mediated drug disposition, target turnover, and drug distribution across ocular tissues and systemic circulation. Following intravitreal administration, lampalizumab achieves rapid equilibration across ocular tissues. Lampalizumab ocular elimination is relatively slow, with a τ1/2 of approximately 3 days, whereas systemic elimination is rapid, with a τ1/2 of 0.8 hours. Target-independent linear clearance is predominant in the eye, whereas target-mediated clearance is predominant in the systemic circulation. Systemic CFD synthesis was estimated to be high (7.8 mg/day); however, the amount of CFD entering the eye due to influx from the systemic circulation was small (<10%) compared with the lampalizumab dose and is thus expected to have an insignificant impact on the clinical dose-regimen decision. Our findings support the clinical use of intravitreal lampalizumab to achieve significant ocular ACP inhibition while maintaining low systemic exposure and minimal systemic ACP inhibition.
authors.affiliation: Genentech, Inc., South San Francisco, California.
authors.forename: Kha N
authors.initials: KN
authors.lastname: Le
authors.forename: Leonid
authors.initials: L
authors.lastname: Gibiansky
authors.forename: Jeremy
authors.initials: J
authors.lastname: Good
authors.forename: Teresa
authors.initials: T
authors.lastname: Davancaze
authors.forename: Menno
authors.initials: M
authors.lastname: van Lookeren Campagne
authors.forename: Kelly M
authors.initials: KM
authors.lastname: Loyet
authors.forename: Alyssa
authors.initials: A
authors.lastname: Morimoto
authors.forename: Jin
authors.initials: J
authors.lastname: Jin
authors.forename: Lisa A
authors.initials: LA
authors.lastname: Damico-Beyer
authors.forename: William D
authors.initials: WD
authors.lastname: Hanley
mesh_terms: D061605:Administration, Intravenous; D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D001082:Aqueous Humor / Q000378:metabolism; D011416:Complement Factor D / Q000037:antagonists & inhibitors*; D005260:Female; D057092:Geographic Atrophy / Q000188:drug therapy / Q000378:metabolism*; D007140:Immunoglobulin Fab Fragments / Q000494:pharmacology* / Q000627:therapeutic use; D058449:Intravitreal Injections; D008252:Macaca fascicularis; D008297:Male; D008954:Models, Biological; D012160:Retina / Q000378:metabolism; D014822:Vitreous Body / Q000378:metabolism
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D007140:Immunoglobulin Fab Fragments; D011416:Complement Factor D; C000603963:lampalizumab